Eli Lilly and Company


Want a discount? Become a member by purchasing Annual Subscription!
SKU: LLY Category:


Eli Lilly’s fundamentals have remained strong throughout the health crises backed by higher demand for drugs like Trulicity, Taltz, and others. The company’s wide range of products treats conditions including cancer, diabetes, immune disorders, and it continues to add promising new pipeline assets through business development deals. In addition to the strong business performance, the company generated revenues of $871.2 million from its Covid-19 therapy, Bamlanivimab that was granted approval for emergency use by the FDA. With the pandemic still on the rise, Eli Lilly is likely to continue to benefit from the use of the treatment. Overall, strong financials, bolt-on acquisitions, and a recession-proof line-up of drugs make us optimistic about the long-term growth trajectory of this healthcare stock and we give it a ‘Buy’ rating.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $496 annual subscription!